Recent Updates
Recently added Catalysts
CGC

CANOPY GROWTH REPORTS FIRST QUARTER FISCAL 2022

Key Takeaway: CANOPY GROWTH REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS SMITHS FALLS, ON - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) today announces its financial results for the first quarter fiscal 2022 ended June 30, 2021. All financial inf

Full Press Release Details

CANOPY GROWTH REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS
SMITHS FALLS, ON - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) today announces its financial results for the first quarter fiscal 2022 ended June 30, 2021. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
"With the right strategy and strong foundation in place we are confident in our ability to deliver long-term success as Canopy's products and brands continue to demonstrate their appeal to consumers in our core markets," said David Klein, CEO, Canopy Growth. "While we're encouraged by regulatory advancement in the U.S., Canopy is not waiting as we continue to scale our business on both sides of the border with an exciting product pipeline planned for the coming quarters."
"We're continuing to drive cost savings and operational efficiencies across the company, and remain broadly on track to our target of $150-$200 million in fiscal 2022- fiscal 2023," added Mike Lee, CFO. "We look forward to scaling our new operating model in coming months as we push forward our profitability goals in fiscal year 2022."
First Quarter Fiscal 2022 Financial Summary
(in millions of Canadian dollars, unaudited) Net revenue Gross margin percentage Adjusted gross margin percentage 2 Net income (loss) Adjusted EBITDA 3 Free cash flow 4
Reported $136.2 20% 21% $390.0 $(63.6) $(186.1)
vs. Q1 2021 23% 1,400 bps 1,400 bps 404% 31% (3%)
First Quarter Fiscal 2022 Business & Operational Highlights
First Quarter Fiscal 2022 Revenue Review
(in millions of Canadian dollars, unaudited) Q1 2022 Q1 2021 vs. Q1 2021
Canadian recreational cannabis
- Business to business 5 $42.7 $34.9 22%
- Business to consumer $17.3 $9.4 84%
$60.0 $44.3 35%
Canadian medical cannabis 6 $13.5 $13.9 (3%)
$73.5 $58.2 26%
International and other
- C 3 $11.4 $15.4 (26%)
- Other $8.0 $5.7 40%
$19.4 $21.1 (8%)
Global cannabis net revenue $92.9 $79.3 17%
Other consumer products
- Storz & Bickel $24.1 $17.1 41%
- This Works $6.5 $6.1 7%
- BioSteel $6.7 $2.4 179%
- Other $6.0 $5.5 9%
Other consumer products revenue $43.3 $31.1 39%
Net revenue $136.2 $110.4 23%
This table has been recast to align with our new segment reporting. International and other revenue includes revenue from our international medical business and hemp-derived CBD business. Other consumer products includes revenue from Storz & Bickel, This Works, BioSteel, clinics, accessories and other ancillary businesses.
(in millions of Canadian dollars, unaudited) Q1 2022 Q1 2021 vs. Q1 2021
Canadian recreational cannabis
- Dry bud 7 $66.0 $40.1 65%
- Oils and softgels 7 $5.7 $7.7 (26%)
- Beverages, edibles, topicals 7 and vapes $9.1 $7.1 28%
- Other revenue adjustments 8 $(3.0) $(3.4) 12%
- Excise taxes $(17.8) $(7.2) (147%)
$60.0 $44.3 35%
Medical cannabis and other
- Dry bud $9.6 $10.8 (11%)
- Oils and softgels $20.5 $25.2 (19%)
- Beverages, edibles, topicals and vapes $4.2 $0.4 950%
- Excise taxes $(1.4) $(1.4) 0%
$32.9 $35.0 (6%)
Global cannabis net revenue $92.9 $79.3 17%
Other consumer products
- Storz & Bickel $24.1 $17.1 41%
- This Works $6.5 $6.1 7%
- BioSteel $6.7 $2.4 179%
- Other $6.0 $5.5 9%
Other consumer products revenue $43.3 $31.1 39%
Net revenue $136.2 $110.4 23%
This table has been recast to align with our new segment reporting.
International Cannabis
Other Consumer Products
The first quarter fiscal 2022 and first quarter fiscal 2021 financial results presented in this press release have been prepared in accordance with U.S. GAAP.
Webcast and Conference Call Information
The Company will host a conference call and audio webcast with David Klein, CEO and Mike Lee, CFO at 10:00 AM Eastern Time on August 6, 2021.
A live audio webcast will be available at:
A replay will be accessible by webcast until 11:59 PM ET on November 4, 2021 at:
Adjusted EBITDA is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted EBITDA is calculated as the reported net income (loss), adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; asset impairment and restructuring costs; restructuring costs recorded in cost of goods sold; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition-related costs. Asset impairments related to periodic changes to the Company's supply chain processes are not excluded from Adjusted EBITDA given their occurrence through the normal course of core operational activities. The Adjusted EBITDA reconciliation is presented within this news release and explained in the Company's Quarterly Report on Form 10-Q to be filed with the SEC.
Free Cash Flow is a non- GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. This measure is calculated as net cash provided by (used in) operating activities less purchases of and deposits on property, plant and equipment. The Free Cash Flow reconciliation is presented within this news release and explained in the Company's Quarterly Report on Form 10-Q to be filed with the SEC.
Adjusted Gross Margin and Adjusted Gross Margin Percentage are non-GAAP measures used by management that are not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Adjusted Gross Margin is calculated as gross margin excluding restructuring and other charges recorded in cost of goods sold, and charges related to the flow-through of inventory step-up on business combinations. Adjusted Gross Margin Percentage is calculated as Adjusted Gross Margin divided by net revenue. The Adjusted Gross Margin and Adjusted Gross Margin Percentage reconciliation is presented within this news release.
Vice President, Investor Relations & Competitive Intelligence
Director, Investor Relations
About Canopy Growth Corporation
Canopy Growth (TSX:WEED,NASDAQ:CGC ) is a world-leading diversified cannabis and cannabinoid-based consumer product company, driven by a passion to improve lives, end prohibition, and strengthen communities by unleashing the full potential of cannabis. Leveraging consumer insights and innovation, we offer product varieties in high quality dried flower, oil, softgel capsule, infused beverage, edible, and topical formats, as well as vaporizer devices by Canopy Growth and industry-leader Storz & Bickel. Our global medical brand, Spectrum Therapeutics, sells a range of full-spectrum products using its colour-coded classification system and is a market leader in both Canada and Germany. Through our award-winning Tweed and Tokyo Smoke banners, we reach our adult-use consumers and have built a loyal following by focusing on top quality products and meaningful customer relationships. Canopy Growth has entered into the health and wellness consumer space in key markets including Canada, the United States, and Europe through BioSteel sports nutrition, and This Works skin and sleep solutions; and has introduced additional federally-permissible CBD products to the United States through our First & Free and Martha Stewart CBD brands. Canopy Growth has an established partnership with Fortune 500 alcohol leader Constellation Brands. For more information visit www.canopygrowth.com.
Notice Regarding Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable securities laws, which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as "intend," "goal," "strategy," "estimate," "expect," "project," "projections," "forecasts," "plans," "seeks," "anticipates," "potential," "proposed," "will," "should," "could," "would," "may," "likely," "designed to," "foreseeable future," "believe," "scheduled" and other similar expressions. Our actual results or outcomes may differ materially from those anticipated. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.
Forward-looking statements include, but are not limited to, statements with respect to:
Certain of the forward-looking statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below.
The forward-looking statements contained herein are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including: (i) management's perceptions of historical trends, current conditions and expected future developments; (ii) our ability to generate cash flow from operations; (iii) general economic, financial market, regulatory and political conditions in which we operate; (iv) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (v) consumer interest in our products; (vi) competition; (vii) anticipated and unanticipated costs; (viii) government regulation of our activities and products including but not limited to the areas of taxation and environmental protection; (ix) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (x) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xi) our ability to conduct operations in a safe, efficient and effective manner; (xii) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our recent acquisitions into our existing operations; (xiii) our ability to continue to operate in light of the COVID-19 pandemic and the impact of the pandemic on demand for, and sales of, our products and our distribution channels; and (xiv) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.
By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking statements in this press release and other reports we file with, or furnish to, the Securities and Exchange Commission (the "SEC") and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, changes in laws, regulations and guidelines and our compliance with such laws, regulations and guidelines; the risk that the COVID-19 pandemic may disrupt our operations and those of our suppliers and distribution channels and negatively impact the demand for and use of our products; consumer demand for cannabis and U.S. hemp products; our limited operating history; the risks and uncertainty regarding future product development; our reliance on licenses issued by and contractual arrangements with various federal, state and provincial governmental authorities; the risk that cost savings and any other synergies from the CBI Group Investments may not be fully realized or may take longer to realize than expected; risks associated with jointly owned investments; risks relating to our current and future operations in emerging markets; future levels of revenues and the impact of increasing levels of competition; risks related to the protection and enforcement of our intellectual property rights; our ability to manage disruptions in credit markets or changes to our credit ratings; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; the success or timing of completion of ongoing or anticipated capital or maintenance projects; risks related to the integration of acquired businesses; the timing and manner of the legalization of cannabis in the United States; business strategies, growth opportunities and expected investment; the adequacy of our capital resources and liquidity, including but not limited to, availability of sufficient cash flow to execute our business plan (either within the expected timeframe or at all); counterparty risks and liquidity risks that may impact our ability to obtain loans and other credit facilities on favorable terms; the potential effects of judicial, regulatory or other proceedings, or threatened litigation or proceedings, on our business, financial condition, results of operations and cash flows; risks related to stock exchange restrictions; risks associated with divestment and restructuring; volatility in and/or degradation of general economic, market, industry or business conditions; our exposure to risks related to an agricultural business, including wholesale price volatility and variable product quality; third-party transportation risks; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis and U.S. hemp products in vaping devices; the anticipated effects of actions of third parties such as competitors, activist investors or federal, state, provincial, territorial or local regulatory authorities, self-regulatory organizations, plaintiffs in litigation or persons threatening litigation; changes in regulatory requirements in relation to our
business and products; and the factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2021. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements.
Forward-looking statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present information about management's current expectations and plans relating to the future, and the reader is cautioned that the forward-looking statements may not be appropriate for any other purpose. While we believe that the assumptions and expectations reflected in the forward-looking statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-looking statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking statements, except as required by law. The forward-looking statements contained in this press release and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements.
CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (in thousands of Canadian dollars, except number of shares and per share data, unaudited)
June 30, 2021 March 31, 2021
ASSETS
Current assets:
Cash and cash equivalents $559,840 $1,154,653
Short-term investments 1,491,286 1,144,563
Restricted short-term investments 14,336 11,332
Amounts receivable, net 106,455 92,435
Inventory 411,675 367,979
Prepaid expenses and other assets 91,584 67,232
Total current assets 2,675,176 2,838,194
Other financial assets 791,658 708,167
Property, plant and equipment 1,142,614 1,074,537
Intangible assets 347,063 308,167
Goodwill 2,000,458 1,889,354
Other assets 9,514 5,061
Total assets $6,966,483 $6,823,480
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $91,339 $67,262
Other accrued expenses and liabilities 79,938 100,813
Current portion of long-term debt 15,705 9,827
Other liabilities 69,148 106,428
Total current liabilities 256,130 284,330
Long-term debt 1,545,073 1,573,136
Deferred income tax liabilities 26,570 21,379
Liability arising from Acreage Arrangement 450,000 600,000
Warrant derivative liability 299,318 615,575
Other liabilities 109,038 107,240
Total liabilities 2,686,129 3,201,660
Commitments and contingencies
Redeemable noncontrolling interest 135,300 135,300
Canopy Growth Corporation shareholders' equity:
Common shares - $nil par value; Authorized - unlimited number of shares; Issued - 393,119,100 shares and 382,875,179 shares, respectively 7,463,557 7,168,557
Additional paid-in capital 2,413,779 2,415,650
Accumulated other comprehensive loss (61,518) (34,240)
Deficit (5,675,738) (6,068,156)
Total Canopy Growth Corporation shareholders' equity 4,140,080 3,481,811
Noncontrolling interests 4,974 4,709
Total shareholders' equity 4,145,054 3,486,520
Total liabilities and shareholders' equity $6,966,483 $6,823,480
CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands of Canadian dollars, except number of shares and per share data, unaudited)
Three months ended June 30,
2021 2020
Revenue $155,423 $119,088
Excise taxes 19,214 8,672
Net revenue 136,209 110,416
Cost of goods sold 108,971 103,921
Gross margin 27,238 6,495
Operating expenses:
Selling, general and administrative expenses 112,574 135,392
Share-based compensation 13,126 30,685
Asset impairment and restructuring costs 89,249 12,794
Total operating expenses 214,949 178,871
Operating loss (187,711) (172,376)
Loss from equity method investments (100) (7,189)
Other income (expense), net 580,666 48,205
Income (loss) before income taxes 392,855 (131,360)
Income tax (expense) recovery (2,900) 3,038
Net income (loss) 389,955 (128,322)
Net loss attributable to noncontrolling interests and redeemable noncontrolling interest (2,463) (19,821)
Net income (loss) attributable to Canopy Growth Corporation $392,418 $(108,501)
Basic earnings (loss) per share $1.02 $(0.30)
Basic weighted average common shares outstanding 384,055,133 363,763,347
Diluted earnings (loss) per share $0.84 $(0.30)
Diluted weighted average common shares outstanding 404,546,243 363,763,347
CANOPY GROWTH CORPORATION CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands of Canadian dollars, unaudited)
Three months ended June 30,
2021 2020
Cash flows from operating activities:
Net income (loss) $389,955 $(128,322)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment 17,116 17,415
Amortization of intangible assets 8,016 16,632
Share of loss on equity method investments 100 7,189
Share-based compensation 13,126 30,685
Asset impairment and restructuring costs 89,249 12,794
Income tax expense (recovery) 2,900 (3,038)
Non-cash foreign currency (17,846) 8,688
Interest paid (23,666) (57)
Change in operating assets and liabilities, net of effects from purchases of businesses:
Amounts receivable (4,946) 17,577
Prepaid expenses and other assets (8,804) (16,059)
Inventory 44,228 (10,772)
Accounts payable and accrued liabilities (16,960) 3,755
Other, including non-cash fair value adjustments (658,248) (75,033)
Net cash used in operating activities (165,780) (118,546)
Cash flows from investing activities:
Purchases of and deposits on property, plant and equipment (20,279) (61,547)
Purchases of intangible assets (833) (3,088)
Proceeds on sale of intangible assets - 18,337
Purchases of short-term investments (346,603) (382,486)
Net cash proceeds on sale of subsidiaries 10,324 -
Sale of (investments in) other financial assets 56 (2,564)
Recovery of amounts related to construction financing - 10,000
Payment of acquisition related liabilities (8,367) (4,511)
Net cash outflow on acquisition of noncontrolling interests - (125)
Net cash outflow on acquisition of subsidiaries (8,857) -
Net cash used in investing activities (374,559) (425,984)
Cash flows from financing activities:
Payment of share issue costs (444) (595)
Proceeds from issuance of shares by RIV Capital - 92
Proceeds from exercise of stock options 3,592 4,722
Proceeds from exercise of warrants - 244,990
Issuance of long-term debt - 4,439
Repayment of long-term debt (48,116) (6,345)
Net cash (used in) provided by financing activities (44,968) 247,303
Effect of exchange rate changes on cash and cash equivalents (9,506) (30,079)
Net decrease in cash and cash equivalents (594,813) (327,306)
Cash and cash equivalents, beginning of period 1,154,653 1,303,176
Cash and cash equivalents, end of period $559,840 $975,870
Adjusted Gross Margin 1 Reconciliation (Non-GAAP Measure)
Three months ended June 30,
(in thousands of Canadian dollars except where indicated; unaudited) 2021 2020
Net revenue $136,209 $110,416
Gross margin, as reported 27,238 6,495
Adjustments to gross margin:
Charges related to the flow-through of inventory step-up on business combinations 1,414 1,213
Adjusted gross margin 1 $28,652 $7,708
Adjusted gross margin percentage 1 21% 7%
1 Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures. See "Non-GAAP Measures".
Adjusted EBITDA 1 Reconciliation (Non-GAAP Measure)
Three months ended June 30,
(in thousands of Canadian dollars, unaudited) 2021 2020
Net income (loss) $389,955 $(128,322)
Income tax expense (recovery) 2,900 (3,038)
Other (income) expense, net (580,666) (48,205)
Loss on equity method investments 100 7,189
Share-based compensation 2 13,126 30,685
Acquisition-related costs 5,780 1,394
Depreciation and amortization 2 25,132 34,047
Asset impairment and restructuring costs 78,618 12,794
Charges related to the flow-through of inventory step-up on business combinations 1,414 1,213
Adjusted EBITDA 1 $(63,641) $(92,243)
1 Adjusted EBITDA is a non-GAAP measure. See "Non-GAAP Measures".
2 From Condensed Interim Consolidated Statements of Cash Flows.
Free Cash Flow Reconciliation 1
Three months ended June 30,
(in thousands of Canadian dollars, unaudited) 2021 2020
Net cash used in operating activities $(165,780) $(118,546)
Purchases of and deposits on property, plant and equipment (20,279) (61,547)
Free cash flow 1 $(186,059) $(180,093)
1 Free cash flow is a non-GAAP measure. See "Non-GAAP Measures".
Segmented Gross Margin Reconciliation
Three months ended June 30,
(in thousands of Canadian dollars, unaudited) 2021 2020
Global cannabis segment
Net revenue $92,939 $79,282
Cost of goods sold 79,570 86,140
Gross margin 13,369 (6,858)
Gross margin percentage 14% (9%)
Other consumer products segment
Revenue $43,270 $31,134
Cost of goods sold 29,401 17,781
Gross margin 13,869 13,353
Gross margin percentage 32% 43%
Segmented Adjusted Gross Margin 1 Reconciliation (Non-GAAP Measure)
Three months ended
(in thousands of Canadian dollars except where indicated; unaudited) June 30, 2021 June 30, 2020
Global cannabis segment
Net revenue $92,939 $79,282
Gross margin, as reported 13,369 (6,858)
Adjustments to gross margin:
Charges related to the flow-through of inventory step-up on business combinations 1,414 -
Adjusted gross margin 1 $14,783 $(6,858)
Adjusted gross margin percentage 1 16% (9%)
Other consumer products segment
Revenue $43,270 $31,134
Gross margin, as reported 13,869 13,353
Adjustments to gross margin:
Charges related to the flow-through of inventory step-up on business combinations - 1,213
Adjusted gross margin 1 $13,869 $14,566
Adjusted gross margin percentage 1 32% 47%
1 Adjusted gross margin and adjusted gross margin percentage are non-GAAP measures. See "Non-GAAP Measures".
Last updated: Aug 6, 2021